United Therapeutics (UTHR) Competitors $308.02 -2.80 (-0.90%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$308.91 +0.89 (+0.29%) As of 03/27/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. ALNY, BIIB, BMRN, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Alnylam Pharmaceuticals Biogen BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings. Do institutionals and insiders hold more shares of ALNY or UTHR? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 11.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to ALNY or UTHR? In the previous week, Alnylam Pharmaceuticals had 42 more articles in the media than United Therapeutics. MarketBeat recorded 62 mentions for Alnylam Pharmaceuticals and 20 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.01 beat Alnylam Pharmaceuticals' score of 0.75 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 25 Very Positive mention(s) 10 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ALNY or UTHR? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B15.61-$278.16M-$2.17-124.89United Therapeutics$2.88B4.81$984.80M$24.6012.52 Is ALNY or UTHR more profitable? United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -12.37%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% United Therapeutics 40.31%19.22%16.15% Do analysts rate ALNY or UTHR? Alnylam Pharmaceuticals currently has a consensus price target of $312.30, suggesting a potential upside of 15.23%. United Therapeutics has a consensus price target of $388.25, suggesting a potential upside of 26.05%. Given United Therapeutics' higher possible upside, analysts plainly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.76United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility and risk, ALNY or UTHR? Alnylam Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Does the MarketBeat Community favor ALNY or UTHR? Alnylam Pharmaceuticals received 561 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.58% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes115876.28% Underperform Votes36023.72% United TherapeuticsOutperform Votes59762.58% Underperform Votes35737.42% SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Remove Ads Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.83B$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio13.537.2023.1319.03Price / Sales4.81226.01383.8993.17Price / Cash16.6365.6738.1634.64Price / Book2.426.476.944.33Net Income$984.80M$141.90M$3.20B$247.06M7 Day Performance-1.78%-3.05%-2.30%-0.52%1 Month Performance-4.82%-4.63%3.10%-3.73%1 Year Performance26.62%-8.61%11.22%1.74% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9404 of 5 stars$308.02-0.9%$388.25+26.0%+26.6%$13.83B$2.88B13.53980Insider TradeShort Interest ↓Positive NewsALNYAlnylam Pharmaceuticals4.2649 of 5 stars$290.70+2.6%$312.30+7.4%+75.5%$37.63B$2.25B-133.962,230High Trading VolumeBIIBBiogen4.9116 of 5 stars$141.60+0.5%$213.33+50.7%-35.1%$20.73B$9.68B12.658,720Positive NewsBMRNBioMarin Pharmaceutical4.9038 of 5 stars$71.99+1.1%$94.00+30.6%-17.8%$13.73B$2.85B32.723,401Options VolumeINCYIncyte4.7096 of 5 stars$62.78+1.4%$74.88+19.3%+6.2%$12.15B$4.24B232.532,617Positive NewsNBIXNeurocrine Biosciences4.9292 of 5 stars$115.60+3.3%$165.24+42.9%-17.3%$11.53B$2.36B35.141,200Analyst ForecastNews CoveragePositive NewsEXELExelixis4.5566 of 5 stars$37.72+2.1%$37.59-0.3%+54.4%$10.56B$2.17B21.311,220Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsEXASExact Sciences4.5798 of 5 stars$47.09+3.2%$70.83+50.4%-32.7%$8.75B$2.76B-8.456,400News CoveragePositive NewsRGENRepligen4.7538 of 5 stars$145.15+3.7%$178.64+23.1%-25.8%$8.15B$634.44M-284.612,020Positive NewsHALOHalozyme Therapeutics4.283 of 5 stars$64.02-1.7%$62.78-1.9%+58.3%$7.91B$1.02B18.66390Positive NewsMDGLMadrigal Pharmaceuticals3.5502 of 5 stars$346.40+1.4%$378.44+9.3%+30.3%$7.65B$180.13M-13.8190Positive News Remove Ads Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives BMRN Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UTHR Stock Free UTHR Stock Alerts